RSV-Preventive Antibody Moves Toward Infant Trial as SK bioscience Submits Application in South Africa

Respiratory syncytial virus (RSV) poses its greatest threat to young infants, making every step especially cautious when preventive drugs move from healthy adults into pediatric research. SK bioscience has submitted a clinical trial application to the South African Health Products Regulatory Authority (SAHPRA) in preparation for launching a global Phase 1b study of RSM01, bringing this preventive antibody into the population for which it is actually intended.

According to the company’s announced plan, the trial is expected to enroll approximately 80 infants aged two weeks to eight months, primarily evaluating safety and pharmacokinetics. The latter will examine the antibody’s concentration and persistence after entering the body, providing a basis for determining doses, dosing intervals, and the design of larger subsequent studies.

RSM01 is a preventive antibody. Conceptually, it directly provides antibodies capable of recognizing the virus, rather than first training the immune system to generate its own response, as a vaccine does. For infants whose immune systems are still developing, this passive immunization strategy has practical appeal; however, whether it can provide sufficient and lasting protection must still be demonstrated in subsequent clinical trials.

The application does not mean that the trial has been approved, nor does it indicate that participant enrollment has begun. SAHPRA must still review the study design and participant protection measures. The company also has not disclosed in the materials provided the dose groups, comparator group, trial sites, recruitment timeline, or specific safety observation period.

Background

RSM01 was originally advanced by the Gates Medical Research Institute through early research and adult Phase 1a development, and SK bioscience obtained the license in February 2026. Moving from adult research into an infant trial means the development program is beginning to directly assess tolerability and behavior in the body within the target population, but at this stage it remains impossible to determine from this whether RSM01 can prevent RSV infection, hospitalization, or severe disease.

The company said the Phase 1b results will be used to decide whether to proceed with subsequent late-stage clinical development. This also underscores the practical significance of this development: it is not an efficacy breakthrough, but a higher-risk threshold in pediatric development. Because the available information comes primarily from a company announcement and there are not yet any infant trial data, RSM01’s safety, protective efficacy, and future clinical positioning remain to be clarified by formal study results.